Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
182.51
-1.67 (-0.91%)
Dec 5, 2025, 4:00 PM EST - Market closed
Quest Diagnostics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Quest Diagnostics stock have an average target of 194.07, with a low estimate of 172 and a high estimate of 215. The average target predicts an increase of 6.33% from the current stock price of 182.51.
Analyst Consensus: Buy
* Price targets were last updated on Oct 27, 2025.
Analyst Ratings
The average analyst rating for Quest Diagnostics stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 8 | 9 | 9 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $190 → $200 | Hold | Maintains | $190 → $200 | +9.58% | Oct 27, 2025 |
| Barclays | Barclays | Hold Maintains $190 → $195 | Hold | Maintains | $190 → $195 | +6.84% | Oct 22, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $195 → $205 | Hold | Maintains | $195 → $205 | +12.32% | Oct 22, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $203 → $210 | Buy | Maintains | $203 → $210 | +15.06% | Oct 21, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $200 → $215 | Strong Buy | Maintains | $200 → $215 | +17.80% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
11.09B
from 9.87B
Increased by 12.37%
Revenue Next Year
11.48B
from 11.09B
Increased by 3.52%
EPS This Year
9.90
from 7.69
Increased by 28.78%
EPS Next Year
10.48
from 9.90
Increased by 5.79%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.6B | 12.2B | |||
| Avg | 11.1B | 11.5B | |||
| Low | 10.7B | 11.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.0% | 9.5% | |||
| Avg | 12.4% | 3.5% | |||
| Low | 8.8% | -0.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.33 | 11.28 | |||
| Avg | 9.90 | 10.48 | |||
| Low | 9.56 | 9.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 34.4% | 13.9% | |||
| Avg | 28.8% | 5.8% | |||
| Low | 24.4% | -2.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.